How AH Clinics Structures HCG Therapy: Dosing, Monitoring, and Patient Selection in Clinical Practice

Human chorionic gonadotropin, or HCG, has been part of reproductive and hormonal medicine for decades, most commonly used to support natural testosterone production in men and to trigger ovulation in women. Because HCG mimics luteinizing hormone, the body's own signal for these processes, clinics that offer it treat it as a prescription therapy requiring lab work and physician oversight, not a self-directed supplement. AH Clinics is one example of how that clinical structure works in practice.

AH Clinics, a physician-supervised anti-aging and hormone therapy clinic in San Diego, California, has operated in the city for more than 10 years, running HCG programs that begin with baseline lab work and continue with scheduled follow-up testing for the length of treatment. According to AH Clinics, that structure includes an individualized dosage, injection frequency, and cycle length set by the clinic's medical team and revisited at each follow-up based on lab results and how the patient is responding.

In clinical practice, HCG is most often used to stimulate the body's own hormone production rather than to replace it directly. In men, it acts on the Leydig cells of the testes to support endogenous testosterone output, which is why it frequently appears alongside testosterone therapy rather than as a standalone treatment. In women, HCG's traditional use is to trigger ovulation as part of fertility care. Its use for weight loss is a separate and more contested application. The FDA took action in 2011 against marketers of over the counter "homeopathic" HCG weight loss products, stating there was no substantial evidence the hormone increases weight loss beyond what results from caloric restriction alone. That regulatory history is a large part of why clinics keep HCG inside a supervised, lab monitored framework instead of marketing it as a standalone weight loss product.

Clinicians typically do not start every patient on the same regimen. Dosing decisions are built around baseline lab values, the patient's stated goal (fertility support, testosterone optimization, or use alongside another hormone protocol), and how the patient responds over the first several weeks of therapy. A clinical intake for HCG generally accounts for:

1. Baseline hormone panels, including markers tied to the patient's stated goal.

2. Medical history and any contraindications to hormone based therapy.

3. Whether HCG is being used alone or alongside another treatment, such as testosterone therapy.

4. The patient's response at early follow-up, which informs whether the plan continues unchanged or is adjusted.

   This individualized approach is standard across reputable hormone clinics. A single fixed dosing schedule applied to every patient, regardless of baseline hormone status, is generally viewed as poor clinical practice.
   

Patients are monitored on a recurring basis, not at a single intake visit. A typical course of physician supervised HCG therapy moves through distinct phases, each with a different clinical focus, as outlined below.

1. Baseline Assessment. Primary Focus: Establish starting hormone status and rule out contraindications. Typical Activity: Intake exam, baseline lab panel, medical history review

2. Active Therapy. Primary Focus: Confirm the protocol is producing the intended hormonal response. Typical Activity: Scheduled follow-up visits, repeat lab work, dosage review

3. Maintenance and Reassessment. Primary Focus: Sustain results and catch needed adjustments early. Typical Activity: Periodic labs, symptom check-ins, protocol continuation or revision
   This staged structure mirrors the broader monitoring principle behind hormone based therapies generally. Per Endocrine Society clinical practice guidelines, patients on hormone therapies should receive baseline laboratory testing followed by periodic monitoring for the duration of treatment, not a single lab draw at intake.

Candidacy is determined by lab findings and clinical history, not by patient preference alone. Men being evaluated for low testosterone, women pursuing ovulation focused fertility care, and patients already on a hormone protocol who may benefit from an adjunct therapy are the categories clinics most often screen for. Patients with certain hormone sensitive conditions, uncontrolled cardiovascular risk factors, or other contraindications identified during intake are generally not candidates for HCG therapy, which is exactly why the baseline lab work and history review happen before any protocol is written, not after.

"We do not hand a patient a dosage on day one," said Dr. Kamron Mirkarimi, MD, a physician with AH Clinics who is board certified in internal medicine. "Every HCG protocol starts with baseline labs and a conversation about the patient's goals, and it gets revisited at every follow-up based on how that patient is actually responding."

AH Clinics runs that same intake-to-monitoring structure across its full slate of services, which spans ten distinct offerings from testosterone therapy and peptide programs to IV and NAD+ infusions and specialty lab testing. The common thread across all of them is that treatment starts with data, not a fixed package.

The underlying hormone biology has not changed, but patient expectations have. As more patients research hormone therapy online before booking a consultation, clinics are leaning harder on transparent, lab-first intake processes rather than one-size-fits-all packages. Heading into 2026, that shift favors clinics willing to explain their monitoring cadence and candidate criteria up front, since patients increasingly compare that information across providers before choosing where to start treatment.

It also reinforces why regulatory scrutiny of unsupervised HCG products has stayed high: the gap between a monitored clinical protocol and an unmonitored product is exactly what the FDA's 2011 action was addressing, and it remains the dividing line today. For anyone weighing a hormone based therapy, the clinical pattern holds regardless of provider: baseline labs first, an individualized protocol second, and monitoring for as long as the therapy continues. That structure is what separates a physician-supervised HCG program from an unregulated product, and it is the framework patients should expect to see, and be able to ask about, before starting treatment anywhere.

(MBT ^PG/AM)